Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era

Allogeneic hematopoietic cell transplantation (allo HCT) remains a valuable alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on allo HCT outcomes in the era of new HL therapies are needed. We evaluated 72 R/R HL patients who received reduced intensity conditioning (RIC) allo HCT...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Bone Marrow Transplant
Autores principales: Hegerova, Livia, Cao, Qing, Lazaryan, Aleksander, McClune, Brian L., Weisdorf, Daniel J., Brunstein, Claudio G., Bachanova, Veronika
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5415418/
https://ncbi.nlm.nih.gov/pubmed/28134921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.357
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares